Search results
Found 470 matches for
A platform to develop biologic therapeutics that outsmart the evolution of antibiotic resistance to save millions of lives.
BioEscalator Bulletin - Summer 2025
4 June 2025
Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Summer 2025 edition of the BioEscalator Bulletin.
Ochre Bio appoints ex-Eli Lilly and AstraZeneca VP as Non-Executive Director
28 May 2025
The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.
Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer
26 May 2025
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as C…
Welcome, Sandbox Bioscience, to the BioEscalator Community!
22 May 2025
We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer
19 May 2025
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointme…
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
5 May 2025
Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has…
Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs
30 April 2025
Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen® and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financia…
Orfonyx Bio – big ambitions in protein upregulation
9 April 2025
Orfonyx Bio is looking to make its mark as a leader in protein upregulation for clinical benefit – and has made technical progress towards this goal over the past two years. In that time as a BioEscalator tenant the University of Oxford spin-out has also grown f…
Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer
8 April 2025
Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company’s lead ‘off-the-shelf’ cancer vaccine…
Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age
7 April 2025
Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the mai…
Dr Mary Vinson joins the U-Ploid as Clinical Development Advisor
5 April 2025
Dr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.
PepGen announces appointment of two new directors to its Board
30 March 2025
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointme…
Moa named one of TIME's top greentech companies in 2025
26 March 2025
Moa recognised as leading global innovator in environmental impact.
Moa forms new biological partnership with NAICONS
25 March 2025
Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.
Infinitopes strengthens Board with two biotech leaders to advance precision immunotherapies into the clinic
20 March 2025
Infinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.
The Gender Advantage: Building Inclusive and Thriving Ventures
20 March 2025
To celebrate International Women's Day 2025, the BioEscalator was delighted to host a double panel discussion and networking event with EnSpire Oxford and Advanced Oxford.
Entelo Bio ushering in new ways of doing science
12 March 2025
Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.
BioEscalator Bulletin - Spring 2025
11 March 2025
Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Spring 2025 edition of the BioEscalator Bulletin.
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
26 February 2025
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Bo…
OXcan President and Co-Founder features as guest speaker on TheHill Digital Innovation Podcast
19 February 2025
Andreas Halner, president and co-founder of Oxford Cancer Analytics (OXcan), chats to TheHill director, Megan Morys-Carter, about the company's inception, what makes the technology so revolutionary and the ever-increasing success OXcan has met with recen…